Lingmou Medical

Lingmou Medical (Hangzhou Lingmou Medical Technology) is a Chinese startup providing department-level solutions for flexible (soft) endoscopes, focused on full-scenario R&D and commercialization of domestic soft endoscopy systems, with a founding team drawn from leading listed industry companies. Its technical edge lies in multi-spectral light-source integration — a "full-scenario imaging" system combining HLI, SVI, TCI, and a domestically exclusive DHI (red-light deep imaging) mode, covering screening through diagnosis to treatment. In April 2025 it raised a Series A of tens of millions of RMB led by Unity Ventures (九合创投), with participation from Chengshu Fenghua and existing shareholder Haibang Fenghua, to accelerate commercialization at home and abroad. Since launching its internationalization strategy in July 2024, it has sold 70+ devices overseas and entered more than 25 core markets across Asia-Pacific, the Middle East, and Latin America — per Unity Ventures, ranking first among new Chinese digestive endoscopy brands in overseas deliveries — while domestically it won placements in major tertiary Grade-A hospitals in its first commercial year.